Acumen Pharmaceuticals, Inc. Product Pipeline Review 2015

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 Reference Code: GMDHC06846CDB Publication Date: MAR 2015 Acumen Pharmaceuticals, Inc. ...
Author: Mercy Grant
0 downloads 0 Views 93KB Size
Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015

Reference Code: GMDHC06846CDB Publication Date: MAR 2015

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 © Global Markets Direct. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(1)

Acumen Pharmaceuticals, Inc. – Product Pipeline Review

Table of Contents Table of Contents ....................................................................................................................................................................... 2 List of Tables ......................................................................................................................................................................... 3 List of Figures ........................................................................................................................................................................ 3 Acumen Pharmaceuticals, Inc. Snapshot..................................................................................................................................... 4 Acumen Pharmaceuticals, Inc. Overview ................................................................................................................................ 4 Key Information ..................................................................................................................................................................... 4 Key Facts .............................................................................................................................................................................. 4 Acumen Pharmaceuticals, Inc. – Research and Development Overview ....................................................................................... 5 Key Therapeutic Areas ........................................................................................................................................................... 5 Acumen Pharmaceuticals, Inc. – Pipeline Review ........................................................................................................................ 7 Pipeline Products by Stage of Development............................................................................................................................ 7 Pipeline Products – Monotherapy ........................................................................................................................................... 8 Acumen Pharmaceuticals, Inc. – Pipeline Products Glance .......................................................................................................... 9 Acumen Pharmaceuticals, Inc. – Early Stage Pipeline Products .............................................................................................. 9 Preclinical Products/Combination Treatment Modalities ...................................................................................................... 9 Acumen Pharmaceuticals, Inc. – Drug Profiles .......................................................................................................................... 10 ACU-193 ............................................................................................................................................................................. 10 Product Description ......................................................................................................................................................... 10 Mechanism of Action ....................................................................................................................................................... 10 R&D Progress ................................................................................................................................................................. 10 ACU-193 Back-up ................................................................................................................................................................ 11 Product Description ......................................................................................................................................................... 11 Mechanism of Action ....................................................................................................................................................... 11 R&D Progress ................................................................................................................................................................. 11 Drugs to Inhibit ADDL Receptor for Alzheimer's Disease ....................................................................................................... 12 Product Description ......................................................................................................................................................... 12 Mechanism of Action ....................................................................................................................................................... 12 R&D Progress ................................................................................................................................................................. 12 Vaccine to Target ADDL for Alzheimer's Disease .................................................................................................................. 13 Product Description ......................................................................................................................................................... 13 Mechanism of Action ....................................................................................................................................................... 13 R&D Progress ................................................................................................................................................................. 13 Acumen Pharmaceuticals, Inc. – Pipeline Analysis .................................................................................................................... 14 Acumen Pharmaceuticals, Inc. – Pipeline Products by Target................................................................................................ 14 Acumen Pharmaceuticals, Inc. – Pipeline Products by Molecule Type ................................................................................... 15 Acumen Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action .......................................................................... 16 Acumen Pharmaceuticals, Inc. – Recent Pipeline Updates......................................................................................................... 17 Acumen Pharmaceuticals, Inc. – Dormant Projects .................................................................................................................... 18 Acumen Pharmaceuticals, Inc. – Locations And Subsidiaries ..................................................................................................... 19 Head Office ......................................................................................................................................................................... 19 Appendix .................................................................................................................................................................................. 20 Methodology ........................................................................................................................................................................ 20

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 © Global Markets Direct. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(2)

Acumen Pharmaceuticals, Inc. – Product Pipeline Review

Coverage ............................................................................................................................................................................ 20 Secondary Research ........................................................................................................................................................... 20 Primary Research ................................................................................................................................................................ 20 Expert Panel Validation ........................................................................................................................................................ 20 Disclaimer ........................................................................................................................................................................... 20

List of Tables Acumen Pharmaceuticals, Inc., Key Information .......................................................................................................................... 4 Acumen Pharmaceuticals, Inc., Key Facts ................................................................................................................................... 4 Acumen Pharmaceuticals, Inc. – Pipeline by Indication, 2015 ...................................................................................................... 6 Acumen Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2015 ................................................................................... 7 Acumen Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2015.................................................................................... 8 Acumen Pharmaceuticals, Inc. – Preclinical, 2015 ....................................................................................................................... 9 Acumen Pharmaceuticals, Inc. – Pipeline by Target, 2015 ......................................................................................................... 14 Acumen Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2015 ............................................................................................. 15 Acumen Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2015 ..................................................................... 16 Acumen Pharmaceuticals, Inc. – Recent Pipeline Updates, 2015 ............................................................................................... 17 Acumen Pharmaceuticals, Inc. – Dormant Developmental Projects,2015.................................................................................... 18

List of Figures Acumen Pharmaceuticals, Inc. – Pipeline by Top 10 Molecule Type, 2015 ................................................................................ 15

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(3)

Acumen Pharmaceuticals, Inc. – Product Pipeline Review

Acumen Pharmaceuticals, Inc. Snapshot Acumen Pharmaceuticals, Inc. Overview Acumen Pharmaceuticals Inc. (Acumen) is a pharmaceutical company. The company discovers and develops therapeutics and diagnostics related to soluble Aß oligomers in Alzheimer’s disease. Its programs include immunotherapy and ACU-193, assembly blocker, and diagnostics. Acumen owns and controls property regarding soluble Abeta oligomers and ADDLs and the related therapeutics and diagnostics. The company's technology concentrates on four strategies to inhibit ADDL disease pathology. Acumen is headquartered in Livermore, California, the US.

Key Information Acumen Pharmaceuticals, Inc., Key Information Web Address Source: Global Markets Direct

Key Facts Acumen Pharmaceuticals, Inc., Key Facts Corporate Address Telephone

No. of Employees

Fax

Fiscal Year End

URL

Revenue (in USD Million)

Industry Source: Global Markets Direct

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 © Global Markets Direct. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(4)

Acumen Pharmaceuticals, Inc. – Product Pipeline Review

Acumen Pharmaceuticals, Inc. – Research and Development Overview Key Therapeutic Areas Acumen Pharmaceuticals, Inc. has promising clinical drug candidates for 1 major therapeutic areas, Central Nervous System. Acumen Pharmaceuticals, Inc. is focused on the development of compounds as these indications have a large market need and these compounds have the potential to offer new benefits to patients and will generate value creating partnerships with pharmaceutical companies. Central Nervous System

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(5)

Acumen Pharmaceuticals, Inc. – Product Pipeline Review

Acumen Pharmaceuticals, Inc. – Pipeline by Indication, 2015 Therapy Area

Indication

Products/Combined Treatment Modalities

Source: Global Markets Direct

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(6)

Acumen Pharmaceuticals, Inc. – Product Pipeline Review

Acumen Pharmaceuticals, Inc. – Pipeline Review Pipeline Products by Stage of Development Acumen Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2015 Stage Development

Products

Source: Global Markets Direct

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(7)

Acumen Pharmaceuticals, Inc. – Product Pipeline Review

Acumen Pharmaceuticals, Inc. – Drug Profiles ACU-193 Product Description

Mechanism of Action

R&D Progress

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(10)

Acumen Pharmaceuticals, Inc. – Product Pipeline Review

ACU-193 Back-up Product Description

Mechanism of Action

R&D Progress

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(11)

Appendix

Appendix Methodology Global Markets Direct’s dedicated Research and Analysis Teams consist of experienced professionals with a pedigree in marketing, market research, consulting background in the pharmaceutical industry and advanced statistical expertise. Global Markets Direct adheres to the Codes of Practice of the Market Research Society (www.mrs.org.uk) and the Strategic and Competitive Intelligence Professionals (www.scip.org). All Global Markets Direct databases are continuously updated and revised. The following research methodology is followed for all databases and reports.

Coverage The objective of updating Global Markets Direct coverage is to ensure that it represents the most up to date vision of the industry possible The report covers all the pharmaceutical/biopharmaceutical products under development across the globe. The scope of the pipeline products coverage aims at setting up the boundaries of the project. It comprises all the therapeutic products that are in the course of development, however, if a drug is solely used for research purpose, where the intention for its further development as a drug is not clear or the strategy for commercialization is not known, the drug is not included in the report. Global Markets Direct aims to cover major news events and deals in the pharmaceutical industry, updated on daily basis. The coverage is further streamlined and strengthened with additional inputs from Global Markets Direct Expert Panel (see below).

Secondary Research The research process begins with exhaustive secondary research on internal and external sources being carried out to source/update the pipeline products information. The secondary research sources that are typically referred to include, but are not limited to: Company websites, annual reports, financial reports, company pipeline chart, broker reports, investor presentations and SEC filings, journals and conferences, clinical trials registries, internal proprietary databases, news articles, press releases and web-casts specific to the companies operating in the respective indication/therapy area.

Primary Research Global Markets Direct conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its pipeline products data. A typical research interview provides first-hand information on the pipeline therapeutics landscape and helps in validating and strengthening the secondary research findings. Primary research involves email interactions with the industry participants across geographies. The participants who typically take part in such a process include, but are not limited to: CEOs, VPs, business development managers, market intelligence managers and national sales managers.

Expert Panel Validation Global Markets Direct uses a panel of experts to cross verify research methodologies, and drive its analytical content. The Global Markets Direct expert panel comprises senior research managers, marketing managers, product specialists & international sales managers.

Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, Global Markets Direct.

Acumen Pharmaceuticals, Inc. – Product Pipeline Review – 2015 © Global Markets Direct. This report is a licensed product and is not to be photocopied

GMDHC06846CDB / Published MAR 2015 Page(20)